Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Frequently asked questions
What sector does Foghorn Therapeutics Inc (FHTX) operate in?
Foghorn Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Foghorn Therapeutics Inc (FHTX) current stock price?
As of the latest data, Foghorn Therapeutics Inc stock price is $6.85, with a previous close of $6.87. Foghorn Therapeutics Inc lost -$0.02 in the last trading session, representing a -0.29% loss.
What is Foghorn Therapeutics Inc (FHTX) current market capitalization?
Foghorn Therapeutics Inc market cap is approximately 406.79 million.
What is Foghorn Therapeutics Inc (FHTX) Earnings Per Share (EPS)?
The trailing EPS is -$0.99, and the forward EPS is -$1.03.
What is Foghorn Therapeutics Inc (FHTX) EBITDA?
Foghorn Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -6.99 million.
Does Foghorn Therapeutics Inc (FHTX) pay dividends?
No. Foghorn Therapeutics Inc does not pay a dividend.
How did Foghorn Therapeutics Inc (FHTX) perform in its most recent earnings report?
In the last report (June 30, 2026), Foghorn Therapeutics Inc posted an EPS surprise of 56.52% and a revenue surprise of 102.57%.
What is Foghorn Therapeutics Inc (FHTX) beta (volatility) score?
Foghorn Therapeutics Inc has a beta of 2.835, indicating very high volatility compared to the market.
